Article Details
Retrieved on: 2021-11-17 21:20:07
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
While the advent of EGFR inhibitors — including gefitinib (AstraZeneca's Iressa), erlotinib (Roche's Tarceva), and more recently, ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here